Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 06, 2021 16:05 ET | Source: ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc. Congratulates uniQure on Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...
September 25, 2020 07:05 ET | Source: uniQure Inc.

uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
September 03, 2020 07:05 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Upcoming Industry Conferences in September

LEXINGTON, Mass. and AMSTERDAM, Sept. 03, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
August 26, 2020 07:05 ET | Source: uniQure Inc.

uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development

LEXINGTON, Mass. and AMSTERDAM, Aug. 26, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...